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Abstract
Background The psychological impact of the COVID-19 outbreak and lockdown on frail populations with advanced Parkinson
disease (APD) and their caregivers may present with peculiar features and require specific interventions.
Methods We enrolled here 100 APD patients and 60 caregivers. Seventy-four patients were treated with device-aided therapies
(DAT) and 26 with standard medical treatment (SMT). Through a telephonic interview, subjects underwent the Hospital Anxiety
and Depression Scale (HADS-A; HADS-D), and an ad hoc questionnaire to explore thoughts and emotions related to the pandemic.
Results Depression was observed in 35% of APD patients and anxiety in 39%, with a significant reduction of the latter after the
lockdown (p= 0.023).We found a significant correlation between the type of therapy and the HADS-A score (p= 0.004). Patients’
main worries were as follows: a possible higher risk of COVID-19 infection (25%), interruption of non-pharmacological
treatments (35%), interruption of outpatient clinics (38%), PD complications related to COVID-19 (47%). Patients treated with
DAT manifested worries about device-related issues and risk for caregivers’ infection. The 40% of caregivers showed anxiety,
while the 21.7% of them showed depression.
Conclusion Our study reveals a higher prevalence of anxiety and the presence of peculiar worries and needs in APD patients
during the pandemic alongside psychological sequelae of their caregivers. These findings are important for neurologists and
healthcare services to foster strategies for the management of psychological distress in both patients and caregivers.
Keywords Parkinson disease . COVID-19 . Anxiety .Worries . Depression
Introduction
On 11 March 2020, the World Health Organization declared
COVID-19 a global pandemic [1]. To prevent contagion,
many countries adopted extraordinary measures such as a
lockdown of social and working activities, with significant
psychological effects on the population [2]. Particular atten-
tion should be paid to the impact of COVID-19 pandemic on
more vulnerable individuals who suffer from chronic diseases,
such as people with Parkinson disease (PD). Due to their path-
ological condition, PD patients are indeed at higher risk for
developing neuropsychiatric symptoms [3].
During pandemic, an increase of psychological distress,
depression, and anxiety have been observed in PD patients
[4–6], which are at least partially related to individual percep-
tion of higher risk for a worse infection outcome [7] and re-
duced access to healthcare services [8].
Importantly, higher distress was observed also in care-
givers of patients with PD [4]. In such a complex picture, a
more specific characterization of the psychological impact of
COVID-19 on PD patients and their families is needed, with a
special focus on the interaction with the heterogeneous motor
and nonmotor symptoms occurring at different clinical stages.
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Advanced PD (APD) is characterized by an increased frailty
related to symptoms’ severity and motor complications that
require frequent therapeutic adjustments [9]. Moreover, APD
patients may be treated by device-aided therapies (DAT),
requesting regular follow-up visits in highly specialized clin-
ical settings [10].
Here, we investigated the psychological impact of the
COVID-19 outbreak on APD patients and their caregivers
by assessing distress, worries, depressive, and anxious symp-
toms; in addition, we evaluated potential differences between
patients treated with DAT compared to those on standard
medical treatment (SMT). We hypothesized an increasing im-
pact of COVID-19 outbreak on PD patients and their care-
givers according to disease severity and treatment complexity.
Methods
Study population
Using the electronic database of the Movement Disorder
Center of the University Hospital of Turin (Italy), we included
all non-demented consenting patients treated with DAT at our
center in the last 5 years, a group of randomly selected non-
demented APD patients treated with SMT (recruited among a
group of consecutive, consenting patients who attended our
center before the lockdown), and their caregivers (from 59%
of patients treated with deep brain stimulation (DBS), 65% of
patients treated with levodopa/carbidopa intestinal gel infu-
sion (LCIG), and 58% of patients on SMT). APD was defined
as persistence of motor fluctuations and/or troublesome dys-
kinesia limiting the activities of daily living in spite of repeat-
ed adjustments of medication [9].
Patients and caregivers enrolled in the current study were
evaluated by phone interview from April 2020 to May 2020
(T0), which was the lockdown interval decided by the Italian
Government. Patients were re-evaluated after lockdown con-
clusion from June 2020 to August 2020 (T1). The Local
Ethical Committee approved the study protocol (Protocol
number: 00194/2020) and each participant gave verbal in-
formed consent.
Data collection
All participants were evaluated with the Hospital Anxiety and
Depression Scale (HADS) at T0 and T1 to obtain a validated
and formal quantification of their depressive and anxious
symptoms [11] considering values ≥ 8 as cut-off. We also
administered a questionnaire specifically developed to inves-
tigate thoughts, fears, and emotions related to COVID-19 out-
break and lockdown, consist ing of 22 questions
(Supplementary Material 1) and divided into 3 sections:
– Section 1: distress and worries related to PD (QUEST-1-
PD), administered to all patients
– Section 2: fears related to deep brain stimulation therapy
(QUEST-2-DBS)
– Section 3: fears related to levodopa/carbidopa intestinal
gel infusion (QUEST-3-LCIG)
Moreover, the following data were collected:
– Information about COVID-19
– Cognitive status, as per the Mini Mental State
Examination (MMSE) score [12], obtained from the eval-
uation of the last 6 months by our clinical archives
Statistical analysis
Descriptive statistics was used for continuous variables and fre-
quency distribution for categorical data. Spearman correlation
tests were performed to analyze correlations between HADS
scores with age, disease duration, MMSE score, presence of
caregivers, type of therapy, and QUEST-1-PD mean score, cal-
culated by answers related to agreement or disagreement (10
questions; range score 1–5). Comparisons between patients and
caregivers for sex, age, education, and HADS scores were ana-
lyzed by Mann-Whitney U test and chi-square test. Differences
in the HADS scores and QUEST-1-PD at T0 between the three
groups of patients were investigated using the non-parametric
Kruskal-Wallis test. Post hoc analyses were run to correct for
multiple comparisons. Wilcoxon test was used for the longitudi-
nal comparisons of patients’ HADS scores between T0 and T1.
All reported p-values are two-tailed. Statistical significance was
set at p < 0.05. All data analyses were run using the Statistical
Package for the Social Sciences (SPSS 26 for Windows,
Chicago, IL).
Results
We enrolled 100 APD patients and 60 caregivers; 54% of pa-
tients were treated with DBS, while 20% of them were on
LCIG and 26% were on SMT; patients were from 14 Italian
Regions (Fig. 1). The 11% of patients spent the lockdown pe-
riod in isolation, while the 89% of them were overseen by at
least one caregiver. Demographic and clinical characteristics of
patients and caregivers are summarized in Tables 1 and 2.
Anxiety and depression assessment
At T0, HADS scores revealed that 39% of patients showed
anxiety and 35% depression. At T1, the percentage was re-
duced for the anxiety (30.6%; p= 0.023) but not for the de-
pression (34.1%; p= 0.807).
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Table 1 Patients’ demographic and clinical characteristics
All patients (n= 100) DBS group (n= 54) LCIG group (n= 20) SMT group (n= 26) p-value









DBS vs LCIG: p= 0.000
DBS vs SMT: p= 1.000
LCIG vs SMT: p= 0.000
Sex (male/female) 60/40 31/23 13/7 16/10 n.a.









DBS vs LCIG: p= 0.000
DBS vs SMT:
p= 1.000
LCIG vs SMT: p= 0.001
Employment Employed
n= 21



























DBS vs LCIG: p= 1.000
DBS vs SMT:
p= 0.028
LCIG vs SMT: p= 0.010














DBS vs LCIG: p= 0.001
DBS vs SMT: p= 0.001
LCIG vs SMT: p= 1.000
Symptoms observed from





















































swab (from February 2020 to T0)
n=0 n=0 n=0 n=0 n.a.
Diagnosis of Covid-19 (from
February 2020 to T0)












DBS vs LCIG: p= 0.028
DBS vs SMT: p= 0.049




































































DBS vs LCIG: p= 0.002
DBS vs SMT: p= 0.065
















The QUEST-1-PD mean score showed a significant corre-
lation with anxiety (p= 0.001) and a trend toward significance
with depression (p= 0.077) at T0. The type of treatment was
significantly correlated to the HADS-A score (p= 0.004), with
LCIG and SMT patients showing the highest prevalence of
anxiety.
At T0, we found no correlation between both anxiety and
depression, and age (HADS-A score: p= 0.158; HADS-D
score: p= 0.193), disease duration (HADS-A score: p=
0.987; HADS-D score: p= 0.559), number of caregivers
(HADS-A score: p= 0.256; HADS-D score: p= 0.493), and
MMSE score (HADS-A score: p= 0.821; HADS-D score: p=
0.057).
At T0, 40% of caregivers showed anxiety and 21.7% de-
pression. A significant difference between patients and care-
givers was found for HADS-D score (p= 0.001).
Specific worries and distress related to COVID-19 and
lockdown
The 25% of patients were feared for a possible higher risk of
infection, the 47% expressed worries about a possible wors-
ening of their PD symptoms due to COVID-19 infection, the
20% about drug supplies, the 38% about limitation of access
to hospital, and the 24% about the difficulty to consult with
physicians or carers (Fig. 2). Moreover, the 35% of patients
were worried about the interruption of non-pharmacological
treatments, such as physiotherapy, psychological support, or
cognitive stimulation, and the 48% about the possible wors-
ening of symptoms consequent to the limitation of outdoor
physical activity. The 39% of patients expressed a positive
opinion about telemedicine, as well as webinars and toll-free
numbers (Fig. 2).
Impact of different therapies
Patients treated with SMT, LCIG, and DBS showed slight,
albeit significant, differences in demographic and clinical fea-
tures (Table 1).
At T0, the anxiety score was significantly higher in SMT
and LCIG patients (HADS-A score: DBS vs LCIG p= 0.028;
DBS vs SMT p= 0.050). At T1, the anxiety score was signif-
icantly higher in LCIG patients (p= 0.002) and maintained a
trend toward statistical significance in SMT patients (p=
0.065). The three groups of patients did not differ for the
presence of a caregiver during the COVID-19 outbreak and
for the mean QUEST-1-PD score.
DBS patients reported specific worries about possible
device-related issues: a percentage of 20.4% (n= 11) of them
were worried about the difficulty to consult the neurologist for
a modification of the stimulation parameters, a percentage of
24.1% (n= 13) about the stimulator charge and the possible
difficulty for replacement, and a percentage of 40.7% (n= 22)
about the interruption of regular follow-up visits. In addition,
35.2% (n= 19) of patients were worried that their caregiver
contracted COVID-19.
LCIG patients reported worries about infection of the sto-
ma (35%, n= 7) or a probe block or dislocation (30%, n= 6). In
addition, a large proportion of them (40%, n= 8) were worried
of a possible block of intestinal infusion of levodopa, or that
their caregiver got affected by COVID-19 (30%, n=6).
Discussion
We evaluated the psychological impact of the COVID-19
pandemic on APD patients and their caregivers, analyzing
specific worries in a large sample of patients who were
Table 1 (continued)
All patients (n= 100) DBS group (n= 54) LCIG group (n= 20) SMT group (n= 26) p-value
Severe (≥16) n= 2 n= 1 n= 0 n= 1
































All data are reported as mean ± standard deviation (range), with the exception of sex, employment, HADS anxiety and depression severity levels,
symptoms observed from February 2020 to T0, execution of nasopharyngeal swab, and diagnosis of Covid-19. n.a., not applicable;MMSE, Mini Mental
State Examination; T0, data collected from April 2020 to May 2020, during the lockdown; T1, data collected after the end of the lockdown in Italy from
June 2020 to August 2020; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS Anxiety subscale; HADS-D, HADS Depression subscale.
Bold values mean statistically significant difference. Significant values adjusted by the Bonferroni correction for multiple tests are reported in italics
*Significant difference between DBS and LCIG
# Significant difference between LCIG and SMT
°Significant difference between DBS and SMT
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stratified for treatment strategies. Anxiety and depression oc-
curred in more than 30% of patients during the lockdown
interval, with improvement of anxiety in the months that
followed the end of lockdown. This confirms previous data
on the negative effect of the COVID-19 outbreak on PD [4–6],
and extend them to patients at advanced disease stages.
Our study highlighted a differential psychological impact
in relation to the treatment of APD patients. Anxiety correlat-
ed with specific distress/worries, investigated by an ad hoc
questionnaire. Most impacting distress factors on patients in-
cluded their perceived higher risk to develop COVID-19 with
a worse outcome, difficulty to have hospital access, and
interruption of non-pharmacological treatments. Patients treat-
ed with DAT reported also specific worries related to their
device dysfunction and the risk for their caregiver to suffer
from COVID-19. In addition, significant anxiety and depres-
sion were observed also in a relevant proportion of caregivers
(40% and 21.7%, respectively).
We argue that the absence of reliable data on the risk for
developing COVID-19 in patients with PD [7] and poor infor-
mation induced feelings of doubts and uncertainty, which in-
creased the level of anxiety; indeed, the need of a correct
information during the outbreak has been claimed by a recent
study [8]. Worries and distress about PD symptoms could also
arise from the restrictions of the lockdown. Physical activity
and non-pharmacological interventions are relevant tools for
managing PD symptoms [13, 14] and the interruption or lim-
itation of these activities has remarkably contributed to in-
crease negative feelings in our patients. Moreover, APD pa-
tients need frequent outpatient visits; in fact, one of the major
concerns reported in our interviewwas related to the limitation
of outpatient clinic access and possible difficulties to consult
with physicians. The limitation of access to healthcare ser-
vices can be, at least partially, mitigated by telemedicine [8,
15], and this issue was appreciated or advocated by almost
half of the patients, underlying the relevance of this different
modality of assistance.
Interestingly, our data showed a correlation between the
type of treatment and anxiety, while no correlation was ob-
served with depression. This indicates that anxiety was likely
related to the strain for PD symptoms management during the
outbreak. Indeed, patients treated with DAT expressed fears
about the possibility to obtain adequate and rapid healthcare
assistance in case of device dysfunction. Another frequent
concern was the risk for the caregiver to develop COVID-
19. The caregiver is indeed regarded by patients as an essential
resource for both symptom management and psychological
support [16]. Noteworthy, anxiety levels were lower in
DBS-treated patients than in LCIG- and SMT-treated patients,
probably for the relatively independent management of the
DBS device.
Our data confirm the findings of other studies that investi-
gated the psychological impact of COVID-19 on PD patients,
highlighting significant emotional sequelae of the pandemic.
In particular, depression was previously reported to occur in
21% of patients, and anxiety in a percentage ranging from 21
to 81.7% of patients [17] and in 57.9% of caregivers [5]. In
addition, increased distress was reported in 43.8% of patients
and 53.1% of caregivers [4].
Our data assessed the psychological consequences of
COVID-19 pandemic in a specific group of PD patients, i.e.,
those with APD, highlighting different emotional and behav-
ioral responses in relation to the type of treatment. This indi-
cates that specific needs should be taken into account for APD
patients. Previous studies assessing the impact of COVID-19
Table 2 Caregivers’ demographic and clinical characteristics
Age 62.1 ± 9.2
(43–83)
Sex (male/female) 21/39





























Execution of nasopharyngeal swab (from
February 2020 to T0)
n=1























All data are reported as mean ± standard deviation (range), with the
exception of sex, employment, HADS anxiety and depression severity
levels, symptoms observed from February 2020 to T0, execution of na-
sopharyngeal swab, and diagnosis of Covid-19. HADS, Hospital Anxiety
and Depression Scale; HADS-A, HADS Anxiety subscale; HADS-D,
HADS Depression subscale; T0, data collected from April 2020 to
May 2020, during the lockdown
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pandemic in patients with PD suggested that the presence of
neuropsychiatric symptoms before the pandemic, as well as
cognitive dysfunction, could predict an increased
psychological distress [18]. This result further supports our
findings on a cohort of APD patients, especially those treated
with DAT, and suggests a strict monitoring for neuropsychiatric
Fig. 1 Distribution of our patients
in the Italian Regions
Fig. 2 Patients’ answers to the QUEST-1-PD exploring distress and worries related to Parkinson disease during the COVID-19 outbreak reported as
percentage
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issues. In this context, telemedicine could be a good option,
with a high level of acceptance by patients according to our
questionnaire and results of previous studies [19].
The main limitation of our study is the lack of baseline
evaluations of anxiety and depression before the COVID-19
outbreak. However, the comparison between two time-points
(T0 and T1) has likely detected a remarkable part of the effects
of the pandemic. Another aspect to be taken into account is
that our cohort focused mostly on APD patients treated with
DAT. Encompassing patients with different therapeutic ap-
proaches may be considered a strength of the study; however,
the presence of only 26% of APD patients treated with SMT
should be considered in the generalization of our findings.
In conclusion, we identified multiple reactions and emo-
tional states in different groups of APD patients, underly-
ing the necessity to strictly monitor the psychological im-
pact of the pandemic in such frail a population. Finally,
specific information strategies and education campaigns
are necessary to reduce distress and anxiety for both pa-
tients and caregivers.
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